Status:
COMPLETED
Preliminary Effectiveness of Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality
Lead Sponsor:
Yale University
Conditions:
Alcohol Use Disorder
Eligibility:
All Genders
21-60 years
Phase:
NA
Brief Summary
State the scientific aim(s) of the study, or the hypotheses to be tested. The purpose of the current study is to evaluate the usage and acceptability of the Soberlink's blood alcohol concentration (BA...
Eligibility Criteria
Inclusion
- are at least 21 years old,
- currently enrolled at Aware In home treatment,
- Primary or secondary DSM-5 diagnosis of alcoholism use disorder (AUD).
Exclusion
- Current suicide or homicide risk,
- meet criteria for DSM-IV current psychotic disorder, or bipolar disorder,
- does not have phone access with text message capabilities
- Unable to read or understand English,
- Unable to complete the study because of anticipated incarceration or move,
- Life-threatening or unstable medical problems,
- No course of current or pending legal action,
- Soberlink results being used for child custody or legal circumstance.
Key Trial Info
Start Date :
June 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT04380116
Start Date
June 29 2020
End Date
May 1 2022
Last Update
May 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aware Recovery Care
North Haven, Connecticut, United States, 06517